Related by context. All words. (Click for frequent words.) 74 systemic lupus erythematosus 72 systemic lupus erythematosus SLE 71 leukemia AML 71 visilizumab 71 canakinumab 70 heterozygous FH 70 SJIA 70 HoFH 69 cilengitide 69 relapsing remitting multiple sclerosis 69 myelodysplastic syndrome MDS 69 autoantibody positive 69 decitabine 69 metastatic renal cell carcinoma 69 lomitapide 68 Gleevec resistant 68 relapsed ovarian cancer 68 diabetic neuropathic pain 68 invasive candidiasis 68 chronic lymphocytic leukemia CLL 68 myelofibrosis 68 diabetic nephropathy 68 Zolinza 68 Alemtuzumab 68 YONDELIS 68 corticosteroid therapy 68 teriflunomide 68 PsA 68 metastatic RCC 68 tocilizumab 68 mRCC 68 HeFH 67 Rheumatoid Arthritis RA 67 fibromyalgia syndrome 67 recurrent glioblastoma multiforme 67 Amrubicin 67 homozygous FH 67 heavily pretreated 67 terlipressin 67 azacitidine 67 Dasatinib 67 Tasimelteon 67 eosinophilic asthma 67 homozygous familial hypercholesterolemia 67 leukemia CLL 67 biologic therapy 67 vandetanib 67 leukemia ALL 67 axitinib 67 pomalidomide 67 pemphigus vulgaris 67 Telintra 67 indolent NHL 67 NYHA Class II 67 refractory gout 67 riociguat 67 aHUS 67 receptor inhibitor 66 ponatinib 66 LymphoStat B belimumab 66 Etanercept 66 efalizumab 66 Golimumab 66 Cimzia TM 66 TNF antagonist 66 sunitinib malate 66 Crohn disease 66 forodesine 66 receptor tyrosine kinase inhibitor 66 antihypertensive therapy 66 phase IIb clinical 66 intravenous cyclophosphamide 66 rheumatoid arthritis 66 Hepatocellular Carcinoma HCC 66 Torisel 66 Certolizumab pegol 66 recurrent glioblastoma 66 lumiliximab 66 Velcade bortezomib 66 BAY #-# 66 Traficet EN 66 metastatic malignant 66 phase IIb trial 66 elotuzumab 66 psoriatic arthritis PsA 66 Nilotinib 66 calcineurin inhibitors 66 cell lymphoma CTCL 66 acute myelogenous leukemia AML 66 acute leukemias 66 rheumatoid arthritis RA 66 recurrent ovarian cancer 66 ACZ# 66 candidemia 66 mTOR inhibitor 66 non metastatic osteosarcoma 66 GvHD 66 Phenoptin 66 Xanafide 66 hereditary deficiency 66 hypercholesterolemic patients 66 post herpetic neuralgia PHN 66 refractory angina 66 sorafenib Nexavar 66 proliferative diabetic retinopathy 66 active ankylosing spondylitis 66 darapladib 66 SHPT 66 OHR/AVR# 66 Vidofludimus 66 AA amyloidosis 66 gastrointestinal stromal tumors GIST 66 RRMS patients 66 relapsed refractory multiple myeloma 65 vidofludimus 65 metastatic malignant melanoma 65 thalidomide Thalomid 65 T2DM 65 PAOD 65 gastrointestinal stromal tumor GIST 65 posaconazole 65 pancreatic neuroendocrine tumors 65 anticancer therapy 65 mycophenolate mofetil 65 immunomodulatory therapy 65 CIMZIA ™ 65 Interferon alpha 65 Hodgkin lymphoma HL 65 nucleoside analogs 65 glufosfamide 65 enzastaurin 65 AA Amyloidosis 65 CIMZIA TM 65 velafermin 65 tyrosine kinase inhibitors 65 anterior uveitis 65 antibody MAb 65 superficial bladder cancer 65 Plicera 65 Natalizumab 65 Mipomersen 65 Archexin 65 sodium glucose cotransporter 65 IV NSCLC 65 Adalimumab 65 HGS# 65 anti leukemic 65 ZOLINZA 65 noninfectious uveitis 65 DMARD therapy 65 BRAF inhibitor 65 Myelofibrosis 65 idiopathic thrombocytopenic purpura ITP 65 ADHF 65 ulcerative colitis UC 65 Pemetrexed 65 myeloproliferative disorders 65 baminercept 65 adalimumab Humira 65 chronic GVHD 65 TACI Ig 65 docetaxel chemotherapy 65 nephrotoxicity 65 infliximab Remicade 65 gefitinib Iressa 65 ACTEMRA 65 TELINTRA 65 benign prostatic hypertrophy BPH 65 BCR ABL inhibitors 65 pegylated interferons 65 HQK 65 Actemra tocilizumab 65 TORISEL 65 cytotoxic chemotherapy 65 ADPKD 65 progressive PsA 65 AGILECT R 65 Symadex 65 Temsirolimus 65 imatinib Gleevec ® 65 idiopathic pulmonary fibrosis IPF 65 Dapagliflozin 65 relapsing multiple sclerosis 65 panobinostat 65 lapatinib Tykerb 65 REMICADE ® 65 secondary hyperparathyroidism 65 INCB# [001] 65 myelodysplastic syndromes 65 Glioblastoma Multiforme 65 metastatic kidney 65 juvenile idiopathic arthritis JIA 65 AEG# 65 chronic myeloid leukemia CML 65 erlotinib Tarceva ® 65 pertuzumab 65 Gleevec imatinib mesylate 65 anti angiogenic agents 65 hematologic disorders 65 invasive fungal infections 65 acute GvHD 65 Epratuzumab 65 micafungin 65 bosutinib 65 relapsing remitting MS RRMS 65 proteasome inhibitor 65 pancreatic NET 65 standard chemotherapy regimens 65 cabazitaxel 65 metastatic lung cancer 65 ankylosing spondylitis AS 64 cutaneous T 64 PRTX 64 sunitinib 64 insulin sensitizers 64 tanespimycin 64 oxypurinol 64 rFVIIa 64 Cloretazine 64 LymphoStat B 64 cisplatin chemotherapy 64 APTIVUS r 64 panitumumab Vectibix 64 TRIOLEX 64 Cushing Syndrome 64 hypercholesterolemia 64 peritumoral brain edema 64 CTAP# Capsules 64 Enzyme Replacement Therapy 64 relapsed MM 64 erlotinib Tarceva 64 dasatinib Sprycel 64 Bezielle 64 rituximab Rituxan 64 neurogenic orthostatic hypotension 64 abatacept 64 VAPRISOL 64 VEGF inhibitors 64 romiplostim 64 olmesartan 64 lupus 64 refractory AML 64 docetaxel Taxotere ® 64 bendamustine 64 bortezomib Velcade 64 daclizumab 64 Nuvion 64 gouty arthritis 64 ACTEMRA TM 64 atypical Hemolytic Uremic Syndrome 64 Chronic lymphocytic leukemia 64 juvenile idiopathic arthritis 64 chlorambucil 64 Myelodysplastic syndromes MDS 64 PEGylated interferon beta 1a 64 Ambrisentan 64 severe sepsis 64 MGd 64 inhibitor RG# 64 pediatric Crohn disease 64 MYLOTARG 64 HBeAg negative 64 diabetic gastroparesis 64 INCB# [003] 64 Virulizin ® 64 AAT deficiency 64 cinacalcet 64 refractory epilepsy 64 SPRYCEL ® 64 investigational monoclonal antibody 64 metastatic renal cell 64 pulmonary arterial hypertension PAH 64 JAK inhibitors 64 symptomatic paroxysmal AF 64 post herpetic neuralgia 64 esophageal candidiasis 64 cardio renal 64 Catena ® 64 Ilaris 64 temsirolimus 64 tyrosine kinase inhibitor 64 deferiprone 64 prostate cancer CaP 64 NATRECOR R 64 atypical hemolytic uremic syndrome 64 Icatibant 64 hepatocellular carcinoma HCC 64 Corlux 64 HIV HCV coinfected 64 ORENCIA R 64 HuMax CD4 64 Bronchiectasis 64 Acute Myeloid Leukemia AML 64 uric acid lowering 64 Tavocept 64 schizophrenia CIAS 64 CYT# potent vascular disrupting 64 disease modifying antirheumatic 64 methotrexate therapy 64 myelodysplastic syndromes MDS 64 CHOP chemotherapy 64 synthetic retinoid 64 Belimumab 64 pulmonary arterial hypertension 64 bucindolol 64 Romiplostim 64 hepatitis C HCV 64 GW# [003] 64 pouchitis 64 hepatocellular carcinoma 64 imatinib Gleevec 64 HuLuc# 64 haematologic 64 mapatumumab 64 acute myeloid leukemia AML 64 generation purine nucleoside 64 Zarnestra 64 interferon therapy 64 antithrombotic 64 hypophosphatasia 64 angiogenesis inhibitor 64 recurrent GBM 64 fluvastatin 64 Systemic Lupus Erythematosus 64 IBS C 64 Nexavar sorafenib 64 Laquinimod 64 Rilonacept 64 metastatic HRPC 64 relapsing remitting 64 idarubicin 64 Severe Primary IGFD 64 vismodegib 64 Pirfenidone 64 imatinib therapy 64 dexanabinol 64 tafamidis 64 vemurafenib 64 castrate resistant prostate cancer 64 TNF inhibitors 64 refractory CLL 64 Vandetanib 63 TTR amyloidosis 63 hepatorenal syndrome 63 myeloproliferative diseases 63 amrubicin 63 Cimzia R 63 phase IIa clinical 63 RoACTEMRA 63 recurrent NSCLC 63 biliary tract cancer 63 MAGE A3 ASCI 63 VA# [002] 63 evaluating tivozanib 63 LY# [003] 63 alvespimycin 63 Neovascular AMD 63 erythropoietic 63 Uricase PEG 63 refractory acute myeloid 63 primary hypercholesterolemia 63 prostate cancer CRPC 63 Lupus Nephritis 63 selective modulator 63 immune thrombocytopenic purpura ITP 63 GSK# [002] 63 TREANDA 63 relapsing MS 63 DFMO 63 PXD# 63 depsipeptide 63 myelofibrosis polycythemia vera 63 bevacizumab Avastin 63 sJIA 63 myelosuppression 63 carcinoid tumors 63 Arcalyst 63 mycophenolate mofetil MMF 63 Crohn disease CD 63 PREZISTA r 63 AEGR 63 myelofibrosis MF 63 sargramostim 63 familial amyloidotic polyneuropathy FAP 63 kidney urologic 63 PROSTVAC ® 63 regorafenib 63 lymphoma CTCL 63 6R BH4 63 dirucotide 63 cancer cachexia 63 dacetuzumab 63 hypomethylating agents 63 cytopenias 63 JAK inhibitor 63 Revlimid lenalidomide 63 Noxafil 63 Doxil ® 63 chronic HCV infection 63 malignant pleural mesothelioma 63 RSD# oral 63 BRIM2 63 Cinquil 63 relapsed refractory 63 tigecycline 63 ara C 63 angiotensin receptor blocker ARB 63 COPAXONE R 63 hypercalcemia 63 Amigal 63 Hsp# inhibitors 63 CMV infection 63 Rasagiline 63 hypereosinophilic syndrome 63 CMV disease 63 sapacitabine 63 PD LID 63 ATACAND 63 renal cell carcinoma 63 ISIS # 63 Omacetaxine 63 postherpetic neuralgia 63 DLBCL 63 IFN beta 63 bone metastasis 63 Rituxan rituximab 63 T1DM 63 therapeutic regimens 63 HER2 positive breast cancer 63 LHRH antagonists 63 INCB# [002] 63 colorectal liver metastases 63 EndoTAG TM -1 63 hematologic toxicity 63 chronic eosinophilic leukemia 63 TREDAPTIVE 63 SUTENT 63 Gleevec imatinib 63 Lung transplantation 63 nonsmall cell lung cancer 63 immunomodulatory 63 hypersensitivity reaction 63 Ofatumumab 63 stage IIIB 63 Sorafenib 63 corticosteroid dexamethasone 63 nucleoside analogue 63 GVHD 63 NUVIGIL 63 smoldering myeloma 63 JAK2 inhibitor 63 dasatinib Sprycel ® 63 HuMax EGFr 63 DACH platinum 63 cediranib 63 EXJADE 63 Eculizumab 63 CA4P 63 sorafenib tablets 63 aripiprazole Abilify 63 rFVIIIFc 63 plasminogen activators 63 rheumatoid arthritis psoriatic arthritis 63 EVIZON 63 Hydroxyurea 63 anti angiogenic therapy 63 Tamibarotene 63 immunomodulator 63 lymphoproliferative disorder 63 HBeAg positive 63 phase IIb study 63 basiliximab 63 ixabepilone 63 diarrhea predominant irritable 63 carcinoid syndrome 63 Vidaza azacitidine 63 mipomersen 63 systemic fungal infections 63 relapsed AML 63 oritavancin 63 ancrod 63 Chronic Myeloid Leukemia 63 essential thrombocythemia 63 INVEGA ® 63 pancreatic insufficiency 63 metastatic melanoma 63 ELACYT 63 Tarceva erlotinib 63 HCV infection 63 adalimumab 63 severe neutropenia 63 ruboxistaurin 63 iniparib 63 TNF Tumor Necrosis Factor 63 neovascular diseases 63 basal cell carcinoma BCC 63 imatinib resistant 63 dirucotide MBP# 63 mixed hyperlipidemia 63 Fabry Disease 63 mycosis fungoides 63 demonstrated antitumor activity 63 renal flares 63 mTOR inhibitors 63 heavily pretreated patients 63 radiation sensitizer 63 beta blocker therapy 63 Benlysta belimumab 63 elevated triglyceride levels 63 tipifarnib 63 ruxolitinib 62 tyrosine kinase inhibitors TKIs 62 immune modulators 62 CD3 monoclonal antibody 62 relapsed leukemia 62 AGHD 62 cannabinor 62 SCCHN 62 Enzastaurin 62 investigational therapies 62 familial hypercholesterolemia 62 refractory metastatic colorectal cancer 62 follicular lymphoma FL 62 Toxicities 62 anti TNF alpha 62 immune thrombocytopenic purpura 62 Ceflatonin 62 calcineurin inhibitor 62 VIDAZA 62 registrational trial 62 fenretinide 62 XmAb# 62 Allergic Rhinitis 62 MPS IVA 62 JAK3 62 Fludara ® 62 Silodosin 62 Cetrorelix 62 Ozarelix 62 trabectedin 62 multiple myeloma 62 placebo controlled clinical 62 lenalidomide Revlimid R 62 DU #b 62 otelixizumab 62 Cell Lymphoma 62 trabedersen 62 potentially hepatotoxic 62 systolic hypertension 62 Deforolimus 62 metastatic neuroendocrine tumors 62 abiraterone 62 invasive aspergillosis 62 Saxagliptin 62 Actemra 62 Cutaneous T 62 debilitating autoimmune 62 tofacitinib 62 MEK inhibitors 62 BARACLUDE ® 62 chronic granulomatous disease 62 lymphocytic leukemia 62 grade cervical intraepithelial 62 iclaprim 62 TBC# 62 Pixantrone 62 Telmisartan 62 IL# PE#QQR 62 stable angina 62 interferon beta therapy 62 Elagolix 62 Vaprisol 62 idiopathic thrombocytopenic purpura 62 Alzhemed TM 62 allogeneic stem cell 62 taxane chemotherapy 62 NOMID 62 sorafenib 62 chronic HCV 62 Ophena TM 62 CIMZIA TM certolizumab pegol 62 opioid induced bowel dysfunction 62 antiarrhythmic drugs 62 FOLOTYN ® 62 rilonacept 62 MYDICAR ® 62 antithrombotic agents 62 refractory NSCLC 62 Vitaxin 62 pramlintide 62 Hodgkin lymphoma NHL 62 Denufosol 62 immunosuppressive therapies 62 LHRH agonists 62 C1 INH 62 Phase IIB 62 briakinumab 62 hour bronchodilation 62 OMNARIS HFA 62 acute myocardial infarction AMI 62 ostarine 62 tolvaptan 62 Lixivaptan 62 elacytarabine 62 intermittent claudication 62 gemcitabine Gemzar ® 62 nilotinib 62 Zytiga 62 Blinatumomab 62 Tolvaptan 62 HCV infected 62 lenalidomide dexamethasone 62 aldosterone antagonists 62 hepatic encephalopathy 62 herpes zoster shingles 62 atacicept 62 Diamyd ® 62 Ocrelizumab 62 methylnaltrexone 62 Arranon 62 Prestara 62 cardiac dysfunction 62 chemotherapeutic agent 62 Alvesco R 62 MULTAQ 62 CTEPH 62 nitazoxanide 62 Maribavir 62 CsA 62 TNF alpha inhibitor 62 systemic juvenile idiopathic 62 biologic therapies 62 Pimavanserin 62 Acute Myeloid Leukaemia AML 62 Actimmune ® 62 alefacept 62 hepatic encephalopathy HE 62 gemifloxacin 62 VZV 62 UPLYSO 62 Abatacept 62 PRT# 62 tumor necrosis 62 Aplidin 62 ganetespib 62 TYZEKA 62 actinic keratosis 62 pheochromocytoma 62 carcinoid 62 infantile spasms 62 nonmetastatic prostate cancer 62 myeloproliferative neoplasms 62 caspofungin 62 gamma secretase inhibitor 62 BENICAR HCT 62 Myelodysplastic Syndrome MDS 62 levodopa therapy 62 xanthine oxidase inhibitor 62 SCH # 62 Genentech Rituxan 62 anti arrhythmic drug 62 Sutent sunitinib 62 hormone refractory prostate cancer 62 abiraterone acetate 62 paricalcitol 62 PEGylated Fab fragment 62 Pazopanib 62 DMARD 62 recurrent genital herpes 62 platinum refractory 62 CANCIDAS 62 relapsed multiple myeloma 62 immune modulator 62 chronic myelogenous leukemia CML 62 rindopepimut 62 prostate cancer HRPC 62 ximelagatran 62 Squalamine 62 multikinase inhibitor 62 pancreatic adenocarcinoma 62 unstable angina UA 62 plasma kallikrein 62 MPS VI 62 severe oral mucositis 62 Cimzia ® 62 immunosuppressive agents 62 pazopanib 62 CBLC# 62 IMC A# 62 Vernakalant 62 AKT inhibitor 62 renal impairment 62 Sym# 62 Cimzia ® certolizumab pegol 62 ragweed allergy 62 Rituximab 62 ATL/TV# 62 vinorelbine 62 nucleoside analog 62 rFIXFc 62 immune modulating 62 antiarrhythmic drug 62 purpura ITP 62 IMGN# 62 cutaneous T cell 62 BENLYSTA ® 62 null responder 62 octreotide 62 bosentan 62 Acute Myelogenous Leukemia AML 62 renal insufficiency 62 Cyclosporine 62 leukotriene receptor antagonist 62 EFAPROXYN 62 Serdaxin 62 immunomodulatory agents 62 pegylated interferon alpha 62 chronic thromboembolic pulmonary 62 mildly symptomatic 62 daptomycin 62 disease modifying 62 MALT lymphoma 62 dyslipidaemia 62 remission induction 62 Fludara 62 systemic scleroderma 62 β blockers 62 Aliskiren 62 chronic myocardial ischemia 62 Vorinostat 62 Clofarabine 62 MKC# MT 62 mixed dyslipidemia 62 tumor lysis syndrome 62 relapsed SCLC 62 Valsartan 62 investigational humanized monoclonal antibody 62 hematopoietic cell 62 UCB Cimzia 62 Irinotecan 62 TNF inhibitor 62 pyridostigmine 62 eltrombopag 62 HuMax CD# 62 smoldering multiple myeloma 62 neurological manifestations 61 acute decompensated heart 61 INS# [001] 61 non squamous NSCLC 61 neovascular 61 eculizumab 61 Bosentan 61 metastatic castration resistant 61 FSAD 61 Enbrel Humira 61 Pseudomonas aeruginosa infections 61 nucleoside analogues 61 virological failure 61 chronic HBV 61 CCR5 antagonist 61 amphotericin B 61 B CLL 61 EGFR inhibitors 61 anti TNF 61 Phase IIb trials 61 CYP #A# 61 refractory chronic myeloid 61 PKC# 61 IMA# 61 alagebrium 61 pediatric acute lymphoblastic 61 Cytoxan 61 choroidal neovascularization 61 galiximab 61 Perforomist Inhalation Solution 61 interferon beta 1b 61 Mitoxantrone 61 VFEND 61 Octreolin 61 octreotide implant 61 CINV 61 Lenocta 61 ALN TTR 61 Dalbavancin 61 Candesartan 61 proteasome inhibitors 61 multi kinase inhibitor 61 vasomotor symptoms 61 arthritis PsA 61 biologic DMARD 61 nonmelanoma skin cancers 61 migraine prophylaxis 61 Idiopathic Pulmonary Fibrosis IPF 61 hematological malignancy 61 Bortezomib 61 cytokine refractory 61 renal toxicity 61 HUMIRA 61 vascular disrupting agent 61 chronic ITP 61 Tyrima 61 antithrombotics 61 Acute Radiation Syndrome ARS 61 NSCLC 61 Aortic stenosis 61 neuroendocrine cancers 61 seropositive patients 61 chronic neuropathic pain 61 adult chronic ITP 61 dasatinib 61 AAT Deficiency 61 acromegalic patients 61 MYCAMINE 61 Acute myeloid leukemia 61 Degarelix 61 Herceptin trastuzumab 61 macroalbuminuria 61 DAPT 61 docetaxel Taxotere R 61 reperfusion injury 61 Avanafil 61 glitazones 61 Pivotal Phase III 61 imatinib resistance 61 Systemic lupus erythematosus SLE 61 erythematosus 61 raltegravir 61 DXL# 61 decompensated liver disease 61 progressive neurodegenerative disorder 61 metreleptin 61 CIPN 61 docetaxel Taxotere 61 recurrent malignant glioma 61 either acutely decompensated 61 alkylating agent 61 brivaracetam 61 MEK inhibitor 61 Celebrex celecoxib 61 Jevtana 61 Lupus nephritis 61 dopaminergic therapy 61 Dacogen injection 61 phase IIa 61 Genz # 61 castration resistant prostate cancer 61 severe hypercholesterolemia 61 ularitide 61 SomatoKine 61 DDP# 61 Ceflatonin R 61 fingolimod 61 grade gliomas 61 Targretin 61 Combination therapy 61 IGIV 61 thromboembolic events 61 tumor xenograft models 61 MabThera Rituxan 61 chronic plaque psoriasis 61 phase III isavuconazole 61 TYGACIL 61 HER2 positive metastatic breast 61 Pulmonary hypertension 61 decompensated heart failure 61 antitumor efficacy 61 Daclizumab 61 clazosentan 61 overactive bladder syndrome 61 Diffuse Large B 61 nosocomial pneumonia 61 Alequel 61 figitumumab 61 NNRTIs 61 paliperidone ER 61 ALT flares 61 Parkinson disease PD 61 fibrotic disease 61 anti EGFR antibody 61 immunomodulators 61 anakinra 61 Hemophilia B 61 Aviptadil 61 ARIKACE ™ 61 KRAS mutant tumors 61 olaparib 61 Fibrillex TM 61 MCyR 61 Neulasta ® 61 HCD# [002] 61 vWD 61 Triolex 61 budesonide foam 61 multiple myeloma MM 61 thromboembolic disease 61 pulmonary hypertension PH 61 deacetylase inhibitors 61 levodopa carbidopa 61 Liprotamase 61 Tofacitinib 61 natalizumab 61 tiapamil 61 beta interferon 61 interferon IFN 61 vWF 61 Janus kinase 61 Severe Sepsis 61 dexpramipexole 61 Tocilizumab 61 latent tuberculosis infection 61 Atrasentan 61 retinal vein occlusion 61 MBP# [001] 61 tramiprosate Alzhemed TM 61 TEMODAL 61 diabetic kidney 61 medullary thyroid cancer 61 Teriflunomide 61 refractory ovarian cancer 61 aerosolized KL4 surfactant 61 oral prodrug 61 Adjuvant chemotherapy 61 hematologic malignancies 61 chronic periodontitis 61 cell malignancies 61 mCRC patients 61 palifermin 61 SNT MC# 61 non hodgkin lymphoma 61 huC# DM4 61 Personalized Immunotherapy 61 bone metastases 61 maribavir 61 clinical pharmacology studies 61 platelet inhibitor 61 pharmacokinetic interactions 61 Carfilzomib 61 transplantation HCT 61 Kepivance 61 ISTODAX 61 pediatric malignancies 61 LHON 61 Safinamide 61 sitaxsentan 61 Friedreich Ataxia FRDA 61 acyclovir Lauriad R 61 Phase Ib clinical 61 Carcinoid tumors 61 chemoradiotherapy 61 interferon alpha 61 Virulizin R 61 hereditary angioedema 61 ocrelizumab 61 Idiopathic Pulmonary Fibrosis 61 Acute Bacterial Sinusitis ABS 61 Psoriatic arthritis 61 BZL# 61 severe gastroparesis 61 relapsing remitting MS 61 Neuvenge 61 NAGS deficiency 61 intravenous bisphosphonates 61 Phase IIIb clinical 61 Pagoclone 61 differentiated thyroid 61 Phase 2a trial 61 nalbuphine ER 61 GnRH agonists 61 Campath alemtuzumab 61 sunitinib Sutent ® 61 Systemic Juvenile Idiopathic 61 HSCT 61 Leber Hereditary Optic Neuropathy 61 acne vulgaris 61 CYPHER Stent 61 Talabostat 61 hypoparathyroidism 61 phase IIb 61 plasma kallikrein inhibitor 61 endothelin receptor antagonists 61 antibody mediated rejection 61 evaluating mipomersen 61 Aflibercept 61 AQ4N 61 tranilast 61 Acute Myeloid Leukemia 61 Evoltra ® 61 cetuximab Erbitux ® 61 Decitabine 61 HCV protease inhibitors 61 Everolimus 61 rNAPc2 61 steroid refractory ulcerative 61 low dose cytarabine 61 Annamycin 61 CytoFabTM 61 HBeAg positive patients 61 Asentar 61 hyperphenylalaninemia HPA due